Sexually transmitted diseases and sexual function

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 2, 2010, Pages 389-413

  Sadeghi Nejad, Hossein ^a   Wasserman, Marlene ^b   Weidner, Wolfgang ^c   Richardson, Daniel ^d   Goldmeier, David ^e  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b Sexual Health Center   (South Africa)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Sexual dysfunction; Sexually transmitted disease; Treatment

Indexed keywords

ACICLOVIR; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; POLLEN EXTRACT; PROTEINASE INHIBITOR; QUERCETIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; SABAL EXTRACT; TAMSULOSIN; WART VIRUS VACCINE; ZIDOVUDINE;

ADJUSTMENT DISORDER; ANXIETY; ARTICLE; BODY IMAGE; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDIASIS; CHRONIC PROSTATITIS; CIRCUMCISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONDOM; CONDYLOMA ACUMINATUM; DEPRESSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; GENITAL HERPES; GONORRHEA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; INFECTION PREVENTION; INFECTION RISK; LOWER URINARY TRACT SYMPTOM; MALE HOMOSEXUAL; MONOTHERAPY; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PELVIS PAIN SYNDROME; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSYCHOTHERAPY; RISK FACTOR; SAFE SEX; SEXISM; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUALLY TRANSMITTED DISEASE; VACCINATION; VULNERABLE POPULATION;

EID: 74049150362     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01622.x     Document Type: Article

References (228)

1. Johnson AM, Mercer CH, Erens B. Sexual behaviour in Britain: Partnerships, practices, and HIV risk behaviours. Lancet 2001, 358:1835-42.
2. Lewden C, Chene G, Morlat P. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007, 46:72-7.
3. Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Community Health 2002, 56:349-53.
4. Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS 2004, 15:234-7.
5. Trotta MP, Ammassari A, Murri R. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS 2008, 22:291-9.
6. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988, 158:1079-83.
7. Valcour V, Shikuma C, Shiramizu B. Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology 2004, 63:822-7.
8. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004, 18(1):S75-8. suppl
9. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999, 13:1249-53.
10. Garvey L, Thomson EC, Main J, Winston A. Response to " persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment. J Acquir Immune Defic Syndr 2007, 46:656-7. author reply 57-8
11. Letendre SL, McCutchan JA, Childers ME. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004, 56:416-23.
12. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001, 33:847-56.
13. Arendt G. Affective disorders in patients with HIV infection: Impact of antiretroviral therapy. CNS Drugs 2006, 20:507-18.
14. Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: The need for a psychiatric presence. Int J Psychiatry Med 1994, 24:103-13.
15. Elliott AJ, Roy-Byrne PP. Major depressive disorder and HIV-1 infection: A review of treatment trials. Semin Clin Neuropsychiatry 1998, 3:137-50.
16. Bing EG, Burnam MA, Longshore D. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001, 58:721-8.
17. Low-Beer S, Chan K, Yip B. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000, 23:295-301.
18. Sacktor N, Lyles RH, Skolasky R. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56:257-60.
19. von Giesen HJ, Hefter H, Jablonowski H, Arendt G. HAART is neuroprophylactic in HIV-1 infection. J Acquir Immune Defic Syndr 2000, 23:380-5.
20. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS 1998, 12:F65-70.
21. Tozzi V, Balestra P, Galgani S. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999, 13:1889-97.
22. Antinori A, Ammassari A, Cinque P. Shift of prevalence and selected characteristics in HIV-1-related neurologic disorders in HAART era: Data from Italian Register Investigative NeuroAIDS (IRINA), in Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections: Foundation for Retrovirology and Human Health. 2001
23. Holzemer WL, Corless IB, Nokes KM. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999, 13:185-97.
24. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000, 19:124-33.
25. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-7.
26. Mao L, Newman CE, Kidd MR, Saltman DC, Rogers GD, Kippax SC. Self-reported sexual difficulties and their association with depression and other factors among gay men attending high HIV-caseload general practices in Australia. J Sex Med 2009, 6:1378-85.
27. Crum-Cianflone NF, Bavaro M, Hale B. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 2007, 21:9-19.
28. Moreno-Perez O, Pico Alfonso AM, Portilla J. Hypogonadism, erectile dysfunction and endothelial dysfunction among HIV-infected men. Med Clin (Barc) 2009, 132:311-21.
29. Richardson D, Goldmeier D, Frize G. Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med 2007, 4:502-8.
30. Goldmeier D, Scullard G, Kapembwa M, Lamba H, Frize G. Does increased aromatase activity in adipose fibroblasts cause low sexual desire in patients with HIV lipodystrophy? Sex Transm Infect 2002, 78:64-6.
31. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-3.
32. Guaraldi G, Luzi K, Murri R. Sexual dysfunction in HIV-infected men: Role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther 2007, 12:1059-65.
33. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004, 38:e79-80.
34. Richardson D, Goldmeier D, Green J, Lamba H, Harris JR. Recommendations for the management of premature ejaculation: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS 2006, 17:1-6.
35. Richardson D, Lamba H, Goldmeier D, Nalabanda A, Harris JR. Factors associated with sexual dysfunction in men with HIV infection. Int J STD AIDS 2006, 17:764-7.
36. Thomas A, LoPicollo J. Sexual functioning in persons with diabetes: Issues in research; treatment, and education. Clin Psychol Rev 1994, 14:61-86.
37. Colebunders R, Smets E, Verdonck K, Dreezen C. Sexual dysfunction with protease inhibitors. Lancet 1999, 353:1802.
38. Newshan G, Taylor B, Gold R. Sexual functioning in ambulatory men with HIV/AIDS. Int J STD AIDS 1998, 9:672-6.
39. Schrooten W, Colebunders R, Youle M. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001, 15:1019-23.
40. Fumaz CR, Munoz-Moreno JA, Molto J. Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005, 38:560-5.
41. Back DJ. Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000, 50:85.
42. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000, 50:99-107.
43. Sekar V, Lefebvre E, De Marez T. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: Phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008, 28:479-85.
44. Rosen RC, Catania JA, Ehrhardt AA. The Bolger conference on PDE-5 inhibition and HIV risk: Implications for health policy and prevention. J Sex Med 2006, 3:960-75. discussion 73-5
45. Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother 2002, 36:1129-34.
46. Jerome RC, Halkitis PN, Siconolfi DE. Club drug use, sexual behavior, and HIV seroconversion: A qualitative study of motivations. Subst Use Misuse 2009, 44:431-47.
47. Stall R, Mills TC, Williamson J. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health 2003, 93:939-42.
48. Sanders SA, Milhausen RR, Crosby RA, Graham CA, Yarber WL. Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage? J Sex Med 2009, 6:1451-6.
49. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:194-201.
50. Crosby R, Yarber WL, Saunders SL, Graham CA. Is phosphodiesterase type 5 inhibitor use associated with condom breakage? Sex Transm Infect 2009, 85:404-5.
51. Dunsmuir WD, Gordon EM. The history of circumcision. BJU Int 1999, 83(1):1-12. suppl
52. Sawires SR, Dworkin SL, Fiamma A, Peacock D, Szekeres G, Coates TJ. Male circumcision and HIV/AIDS: Challenges and opportunities. Lancet 2007, 369:708-13.
53. Adami HO, Trichopoulos D. Cervical cancer and the elusive male factor. N Engl J Med 2002, 346:1160-1.
54. Castellsague X, Bosch FX, Munoz N. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002, 346:1105-12.
55. Schoen EJ, Oehrli M, Colby C, Machin G. The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics 2000, 105:E36.
56. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: A systematic review of randomised trials and observational studies. Arch Dis Child 2005, 90:853-8.
57. Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: A systematic review and meta-analysis. Sex Transm Infect 2006, 82:101-9. discussion 10
58. Orroth KK, Freeman EE, Bakker R. Understanding the differences between contrasting HIV epidemics in east and west Africa: Results from a simulation model of the Four Cities Study. Sex Transm Infect 2007, 83(1):i5-16. suppl
59. Fink AJ. A possible explanation for heterosexual male infection with AIDS. N Engl J Med 1986, 315:1167.
60. Simonsen JN, Cameron DW, Gakinya MN. Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med 1988, 319:274-8.
61. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med 2005, 2:e298.
62. Bailey RC, Moses S, Parker CB. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007, 369:643-56.
63. Gray RH, Kigozi G, Serwadda D. Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 2007, 369:657-66.
64. Westercamp N, Bailey RC. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: A review. AIDS Behav 2007, 11:341-55.
65. Gray RH, Li X, Kigozi G. The impact of male circumcision on HIV incidence and cost per infection prevented: A stochastic simulation model from Rakai, Uganda. AIDS 2007, 21:845-50.
66. Donoval BA, Landay AL, Moses S. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006, 125:386-91.
67. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995, 85:475-84.
68. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006, 20:1491-5.
69. Patterson BK, Landay A, Siegel JN. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002, 161:867-73.
70. Szabo R, Short RV. How does male circumcision protect against HIV infection? BMJ 2000, 320:1592-4.
71. Muula AS, Prozesky HW, Mataya RH, Ikechebelu JI. Prevalence of complications of male circumcision in Anglophone Africa: A systematic review. BMC Urol 2007, 7:4.
72. Krieger JN, Bailey RC, Opeya JC. Adult male circumcision outcomes: Experience in a developing country setting. Urol Int 2007, 78:235-40.
73. Kell P, Sadeghi-Nejad H, Price D. An ethical dilemma: Erectile dysfunction in the HIV-positive patient: To treat or not to treat. Int J STD AIDS 2002, 13:355-7.
74. Sadeghi-Nejad H, Watson R, Irwin R, Nokes K, Gern A, Price D. Lecture 5: Erectile dysfunction in the HIV-positive male: A review of medical, legal and ethical considerations in the age of oral pharmacotherapy. Int J Impot Res 2000, 12(3):S49-53. suppl
75. Stemple L. Health and human rights in today's fight against HIV/AIDS. AIDS 2008, 22(2):S113-21. suppl
76. Fink KS, Carson CC, DeVellis RF. Adult circumcision outcomes study: Effect on erectile function, penile sensitivity, sexual activity and satisfaction. J Urol 2002, 167:2113-6.
77. Senkul T, Iser IC, sen B, KarademIr K, Saracoglu F, Erden D. Circumcision in adults: Effect on sexual function. Urology 2004, 63:155-8.
78. Collins S, Upshaw J, Rutchik S, Ohannessian C, Ortenberg J, Albertsen P. Effects of circumcision on male sexual function: Debunking a myth? J Urol 2002, 167:2111-2.
79. Kigozi G, Watya S, Polis CB. The effect of male circumcision on sexual satisfaction and function, results from a randomized trial of male circumcision for human immunodeficiency virus prevention, Rakai, Uganda. BJU Int 2008, 101:65-70.
80. Krieger JN, Mehta SD, Bailey RC. Adult male circumcision: Effects on sexual function and sexual satisfaction in Kisumu, Kenya. J Sex Med 2008, 5:2610-22.
81. Schoen EJ, Colby CJ, To TT. Cost analysis of neonatal circumcision in a large health maintenance organization. J Urol 2006, 175:1111-5.
82. Bell C, Richardson D, Wall M, Goldmeier D. HIV-associated female sexual dysfunction-Clinical experience and literature review. Int J STD AIDS 2006, 17:706-9.
83. Solursh DS, Ernst JL, Lewis RW. The human sexuality education of physicians in North American medical schools. Int J Impot Res 2003, 15(5):S41-5. suppl
84. Gupta RN, Wyatt GE, Swaminathan S. Correlates of relationship, psychological, and sexual behavioral factors for HIV risk among Indian women. Cultur Divers Ethnic Minor Psychol 2008, 14:256-65.
85. Wood K, Jewkes R. Violence, rape, and sexual coercion: Everyday love in a South African township. Gend Dev 1997, 5:41-6.
86. Ellen W. Factors That Influence Risk Behavior in HIV Infected Women Receiving Antiretroviral Therapy in Kampala and Masaka Uganda. 2007, 159. MacLachlan, PhD Dissertation
87. Bancroft J, Loftus J, Long JS. Distress about sex: A national survey of women in heterosexual relationships. Arch Sex Behav 2003, 32:193-208.
88. Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: A cross sectional population survey. J Epidemiol Community Health 1999, 53:144-8.
89. Meyer-Bahlburg HF, Nostlinger C, Exner TM. Sexual functioning in HIV+ and HIV-injected drug-using women. J Sex Marital Ther 1993, 19:56-68.
90. Hankins C, Gendron S, Tran T, Lamping D, Lapointe N. Sexuality in Montreal women living with HIV. AIDS Care 1997, 9:261-71.
91. Goggin K, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: An exploratory study. Psychosom Med 1998, 60:11-6.
92. Brown GR, Kendall S, Ledsky R. Sexual dysfunction in HIV seropositive women without AIDS. J Psychol Hum Sex 1995, 7:73-97.
93. Denis A, Hong SM. Sexual functioning of women with HIV: A comparison with non HIV women. Can J Hum Sex 2003, 12:97-107.
94. Bouhnik AD, Preau M, Schiltz MA, Obadia Y, Spire B. Sexual difficulties in people living with HIV in France-Results from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA). AIDS Behav 2008, 12:670-6.
95. Florence E, Schrooten W, Dreezen C. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care 2004, 16:550-7.
96. Siegel K, Karus D, Dean L. Psychosocial characteristics of New York City HIV-infected women before and after the advent of HAART. Am J Public Health 2004, 94:1127-32.
97. Schrimshaw EW, Siegel K, Lekas HM. Changes in attitudes toward antiviral medication: A comparison of women living with HIV/AIDS in the pre-HAART and HAART eras. AIDS Behav 2005, 9:267-79.
98. Bova C, Durante A. Sexual functioning among HIV-infected women. AIDS Patient Care STDS 2003, 17:75-83.
99. Lambert S, Keegan A, Petrak J. Sex and relationships for HIV positive women since HAART: A quantitative study. Sex Transm Infect 2005, 81:333-7.
100. Keegan A, Lambert S, Petrak J. Sex and relationships for HIV-positive women since HAART: A qualitative study. AIDS Patient Care STDS 2005, 19:645-54.
101. Siegel K, Schrimshaw EW, Lekas HM. Diminished sexual activity, interest, and feelings of attractiveness among HIV-infected women in two eras of the AIDS epidemic. Arch Sex Behav 2006, 35:437-49.
102. Morrow K, Costello T, Boland R. Understanding the psychosocial needs of HIV-positive women: A qualitative study. Psychosomatics 2001, 42:497-503.
103. Ball J, Tannenbaum L, Armistead L, Maguen S. Coping and HIV infection in African-American women. Women Health 2002, 35:17-36.
104. Tien PC, Schneider MF, Cole SR. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007, 21:1739-45.
105. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors. AIDS 2008, 22(3):S19-26. suppl
106. Jerico C, Knobel H, Calvo N. Subclinical carotid atherosclerosis in HIV-infected patients: Role of combination antiretroviral therapy. Stroke 2006, 37:812-7.
107. Compostella C, Compostella L, D'Elia R. The symptoms of autonomic dysfunction in HIV-positive Africans. Clin Auton Res 2008, 18:6-12.
108. Sattler FR. Pathogenesis and treatment of lipodystrophy: What clinicians need to know. Top HIV Med 2008, 16:127-33.
109. Tien PC. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562-71.
110. Huang JS, Harrity S, Lee D, Becerra K, Santos R, Mathews WC. Body image in women with HIV: A cross-sectional evaluation. AIDS Res Ther 2006, 3:17.
111. Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care 2006, 18:663-73.
112. Sharma A, Howard AA, Schoenbaum EE, Buono D, Webber MP. Body image in middle-aged HIV-infected and uninfected women. AIDS Care 2006, 18:998-1003.
113. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther 2007, 4:19.
114. Mutimura E, Stewart A, Crowther NJ, Yarasheski KE, Cade WT. The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Qual Life Res 2008, 17:377-85.
115. Orlando G, Guaraldi G, De Fazio D. Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eight-week observational, nonrandomized study. AIDS Patient Care STDS 2007, 21:833-42.
116. Grinspoon S, Corcoran C, Miller K. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997, 82:1332-7.
117. Hadigan C, Corcoran C, Piecuch S, Rodriguez W, Grinspoon S. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. J Clin Endocrinol Metab 2000, 85:3544-50.
118. Johnsen S, Dolan SE, Fitch KV, Killilea KM, Shifren JL, Grinspoon SK. Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. J Clin Endocrinol Metab 2005, 90:5596-604.
119. Graham CA, Bancroft J, Doll HA, Greco T, Tanner A. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? Psychoneuroendocrinology 2007, 32:246-55.
120. Dolan S, Wilkie S, Aliabadi N. Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: A randomized placebo-controlled study. Arch Intern Med 2004, 164:897-904.
121. Herbst KL, Calof OM, Hsia SH. Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus-infected women with mild to moderate weight loss. Fertil Steril 2006, 85:1794-802.
122. Lee YW, Eum SY, Nath A, Toborek M. Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells. Cardiovasc Res 2004, 63:139-48.
123. Wilson ME, Dimayuga FO, Reed JL. Immune modulation by estrogens: Role in CNS HIV-1 infection. Endocrine 2006, 29:289-97.
124. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008, 13:123-32.
125. Desquilbet L, Deveau C, Goujard C, Hubert JB, Derouineau J, Meyer L. Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. AIDS 2002, 16:2329-33.
126. Dago-Akribi HA, Adjoua MCC. Psychosexual development among HIV positive adolescents in Abidjan, Cote d'Ivoire. Reprod Health Matters 2004, 12:19-28.
127. Wiener LS, Battles HB, Wood LV. A longitudinal study of adolescents with perinatally or transfusion acquired HIV infection: Sexual knowledge, risk reduction self-efficacy and sexual behavior. AIDS Behav 2007, 11:471-8.
128. Massad LS, Evans CT, Wilson TE. Impact of menopause on condom use by HIV-seropositive and comparison seronegative women. J Acquir Immune Defic Syndr 2008, 47:401-2.
129. Samuel M, Taylor C, Brady M, McDonald C, Poulton M, Tenant-Flowers M. Awareness of HIV post-exposure prophylaxis after sexual exposure and emergency hormonal contraception in HIV-positive women. Int J STD AIDS 2008, 19:14-5.
130. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006, 12:5.
131. Campisi G, Giovannelli L. Controversies surrounding human papilloma virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol 2009, 1:8.
132. Paavonen J, Naud P, Salmeron J. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-14.
133. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-27. The FUTURE II Study Group
134. Conaglen HM, Hughes R, Conaglen JV, Morgan J. A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus. Int J STD AIDS 2001, 12:651-8.
135. Graziottin A, Serafini A. HPV infection in women: Psychosexual impact of genital warts and intraepithelial lesions. J Sex Med 2009, 6:633-45.
136. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998, 9:571-8.
137. Reed BD, Ruffin MT, Gorenflo DW, Zazove P. The psychosexual impact of human papillomavirus cervical infections. J Fam Pract 1999, 48:110-6.
138. Voog E, Lowhagen GB. Follow-up of men with genital papilloma virus infection. Psychosexual aspects. Acta Derm Venereol 1992, 72:185-6.
139. Xu F, Sternberg MR, Kottiri BJ. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-73.
140. Fleming DT, McQuillan GM, Johnson RE. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997, 337:1105-11.
141. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Ann Intern Med 1983, 98:958-72.
142. Strick LB, Wald A. Diagnostics for herpes simplex virus: Is PCR the new gold standard? Mol Diagn Ther 2006, 10:17-28.
143. Lafferty WE, Krofft S, Remington M. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987, 25:323-6.
144. Goldmeier D, Garvey L, Barton S. Does chronic stress lead to increased rates of recurrences of genital herpes-A review of the psychoneuroimmunological evidence? Int J STD AIDS 2008, 19:359-62.
145. Mindel A, Marks C. Psychological symptoms associated with genital herpes virus infections: Epidemiology and approaches to management. CNS Drugs 2005, 19:303-12.
146. Green J, Ferrier S, Kocsis A. Determinants of disclosure of genital herpes to partners. Sex Transm Infect 2003, 79:42-4.
147. Corey L, Wald A, Patel R. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
148. Wald A, Langenberg AG, Krantz E. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005, 143:707-13.
149. Kerkering K, Gardella C, Selke S, Krantz E, Corey L, Wald A. Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks. Obstet Gynecol 2006, 108:947-52.
150. Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Recurrent genital herpes treatments and their impact on quality of life. Pharmacoeconomics 2003, 21:853-63.
151. Carney O, Ross E, Ikkos G, Mindel A. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993, 69:457-9.
152. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007, 83:359-64.
153. Richards J, Scholes D, Caka S. HSV-2 serologic testing in an HMO population: Uptake and psychosocial sequelae. Sex Transm Dis 2007, 34:718-25.
154. Rosenthal SL, Zimet GD, Leichliter JS. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect 2006, 82:154-7. discussion 57-8
155. Celum C, Wald A, Hughes J. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:2109-19.
156. Hudson CP. Effect of aciclovir on HIV-1 acquisition in HSV-2-positive patients. Lancet 2008, 372:9-98. author reply
157. Campbell R, Mills N, Sanford E, Graham A, Low N, Peters TJ. Does population screening for Chlamydia trachomatis raise anxiety among those tested? Findings from a population based chlamydia screening study. BMC Public Health 2006, 6:106.
158. Darroch J, Myers L, Cassell J. Sex differences in the experience of testing positive for genital chlamydia infection: A qualitative study with implications for public health and for a national screening programme. Sex Transm Infect 2003, 79:372-3.
159. Mills N, Daker-White G, Graham A, Campbell R. Population screening for Chlamydia trachomatis infection in the UK: A qualitative study of the experiences of those screened. Fam Pract 2006, 23:550-7.
160. Pavlin NL, Gunn JM, Parker R, Fairley CK, Hocking J. Implementing chlamydia screening: What do women think? A systematic review of the literature. BMC Public Health 2006, 6:221.
161. Kangas I, Andersen B, Olesen F, Moller JK, Ostergaard L. Psychosocial impact of Chlamydia trachomatis testing in general practice. Br J Gen Pract 2006, 56:587-93.
162. Champion JD, Shain RN, Piper J, Perdue ST. Psychological distress among abused minority women with sexually transmitted diseases. J Am Acad Nurse Pract 2002, 14:316-24.
163. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004, 82:454-61.
164. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: Report on a United Kingdom cohort. Br J Obstet Gynaecol 1995, 102:407-14.
165. Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis 2008, 21:65-9.
166. Risser WL, Risser JM. The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: A structured review. Int J STD AIDS 2007, 18:727-31.
167. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: Systematic review. BMJ 2006, 332:749-55.
168. Elmerstig E, Wijma B, Bertero C. Why do young women continue to have sexual intercourse despite pain? J Adolesc Health 2008, 43:357-63.
169. Lalos A, Lalos O, Jacobsson L, von Schoultz B. The psychosocial impact of infertility two years after completed surgical treatment. Acta Obstet Gynecol Scand 1985, 64:599-604.
170. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999, 282:236-7.
171. Schaeffer AJ, Anderson RU, Krieger JN, McConnell J, Abrams P, Denis L. Statement on prostatitis. The assessment and management of male pelvic pain syndrome including prostatitis. International conference on new developments in prostate cancer and prostate diseases 2006, 342-75. In, eds., 6th, Paris, Health Publications
172. Burger B, Weidner W, Altwein JE. Prostate and sexuality: An overview. Eur Urol 1999, 35:177-84.
173. Mehik A, Hellstrom P, Sarpola A, Lukkarinen O, Jarvelin MR. Fears, sexual disturbances and personality features in men with prostatitis: A population-based cross-sectional study in Finland. BJU Int 2001, 88:35-8.
174. Weidner W, Anderson RU. Evaluation of acute and chronic bacterial prostatitis and diagnostic management of chronic prostatitis/chronic pelvic pain syndrome with special reference to infection/inflammation. Int J Antimicrob Agents 2008, 31(1):S91-5. suppl
175. Weidner W, Wagenlehner FM, Marconi M, Pilatz A, Pantke KH, Diemer T. Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: Andrological implications. Andrologia 2008, 40:105-12.
176. Litwin MS, McNaughton-Collins M, Fowler FJ. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999, 162:369-75.
177. Schneider H, Wilbrandt K, Ludwig M, Beutel M, Weidner W. Prostate-related pain in patients with chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2005, 95:238-43.
178. WHO manual for the standardized investigation and diagnosis of the infertile couple: WHO manual for the standardized investigation and diagnosis of the infertile couple. 1993, WHO
179. Mazzoli S, Cai T, Rupealta V. Interleukin 8 and anti-Chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 2007, 51:1385-93.
180. Schneede P, Tenke P, Hofstetter AG. Sexually transmitted diseases (STDs)-a synoptic overview for urologists. Eur Urol 2003, 44:1-7.
181. Weidner W, Diemer T, Huwe P, Rainer H, Ludwig M. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002, 19:466-70.
182. Keltikangas-Jarvinen L, Jarvinen H, Lehtonen T. Psychic disturbances in patients with chronic prostatis. Ann Clin Res 1981, 13:45-9.
183. Berghuis JP, Heiman JR, Rothman I, Berger RE. Psychological and physical factors involved in chronic idiopathic prostatitis. J Psychosom Res 1996, 41:313-25.
184. Jacobsen SJ, Jacobson DJ, Rohe DE, Girman CJ, Roberts RO, Lieber MM. Frequency of sexual activity and prostatic health: Fact or fairy tale? Urology 2003, 61:348-53.
185. Lutz MC, Roberts RO, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Cross-sectional associations of urogenital pain and sexual function in a community based cohort of older men: Olmsted county, Minnesota. J Urol 2005, 174:624-8.
186. O'Leary MP, Fowler FJ, Lenderking WR. A brief male sexual function inventory for urology. Urology 1995, 46:697-706.
187. Marszalek M, Wehrberger C, Temml C, Ponholzer A, Berger I, Madersbacher S. Chronic pelvic pain and lower urinary tract symptoms in both sexes: Analysis of 2,749 participants of an urban health screening project. Eur Urol 2009, 55:499-507. Feb, Epub 2008 Apr 1.
188. Qiu YC, Xie CY, Zeng XD, Zhang JH. Investigation of sexual function in 623 patients with chronic prostatitis. Zhonghua Nan Ke Xue 2007, 13:524-6.
189. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-30.
190. Anderson RU, Wise D, Sawyer T, Chan CA. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: Improvement after trigger point release and paradoxical relaxation training. J Urol 2006, 176:1534-8.
191. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004, 93:568-70.
192. Lee SW, Liong ML, Yuen KH. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology 2008, 71:79-84.
193. Trinchieri A, Magri V, Cariani L. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Arch Ital Urol Androl 2007, 79:67-70.
194. Gonen M, Kalkan M, Cenker A, Ozkardes H. Prevalence of premature ejaculation in Turkish men with chronic pelvic pain syndrome. J Androl 2005, 26:601-3.
195. Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 2001, 58:198-202.
196. Ilie CP, Mischianu DL, Pemberton RJ. Painful ejaculation. BJU Int 2007, 99:1335-9.
197. Weidner W, Ludwig M, Miller J. Therapy in male accessory gland infection-what is fact, what is fiction? Andrologia 1998, 30(1):87-90. suppl
198. Roehrborn C, Kaplan SA, Noble WD, Lucia MS, Slawin KM, McVary KT, Kusek JW, Nyberg LM. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results of the MTOP study (abstract). J Urol 2005, 173:204.
199. Penna G, Mondaini N, Amuchastegui S. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007, 51:524-33.
200. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004, 46:547-54.
201. Nickel JC, Elhilali M, Vallancien G. Benign prostatic hyperplasia (BPH) and prostatitis: Prevalence of painful ejaculation in men with clinical BPH. BJU Int 2005, 95:571-4.
202. Muller A, Mulhall JP. Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 2005, 15:404-9.
203. Tripp DA, Nickel JC, Ross S, Mullins C, Stechyson N. Prevalence, symptom impact and predictors of chronic prostatitis-like symptoms in Canadian males aged 16-19 years. BJU Int 2009, 103:1080-4.
204. Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009, 73:538-42. discussion 42-3
205. Nickel JC, Elhilali M, Emberton M, Vallancien G. The beneficial effect of alfuzosin 10 mg once daily in " real-life" practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int 2006, 97:1242-6.
206. Wagenlehner FM, Weidner W. Prostatitis: No benefit of alpha-blockers for chronic prostatitis. Nat Rev Urol 2009, 6:183-4.
207. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007, 4:368-78.
208. Nickel JC, Krieger JN, McNaughton-Collins M. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008, 359:2663-73.
209. Weidner W. Treating chronic prostatitis: Antibiotics no, alpha-blockers maybe. Ann Intern Med 2004, 141:639-40.
210. Alexander RB, Propert KJ, Schaeffer AJ. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: A randomized, double-blind trial. Ann Intern Med 2004, 141:581-9.
211. Shoskes DA. Phytotherapy in chronic prostatitis. Urology 2002, 60:35-7. discussion 37
212. Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: A multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009, 56(3):544-51. Sep, Epub 2009 Jun 3.
213. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007, 51:1717-23.
214. Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007, 69:25-6.
215. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006, 49:740-5.
216. Buve A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002, 359:2011-7.
217. Lule E, Bank HDN-TW. Strengthening the linkages between reproductive health and HIV/AIDS programs. 1-14. In, ed., Washington, DC, Undated-Draft
218. Stulhofer A, Graham C, Bozicevic I, Kufrin K, Ajdukovic D. An assessment of HIV/STI vulnerability and related sexual risk-taking in a nationally representative sample of young Croatian adults. Arch Sex Behav 2009, 38:209-25.
219. Melkote SR, Muppidi SR, Goswami D. Social and economic factors in an integrated behavioral and societal approach to communications in HIV/AIDS. J Health Commun 2000, 5:17-27. suppl
220. Intimate Partner Violence and HIV/AIDS: The Global Coalition on Women and AIDS. Violence against Women and HIV/AIDS -Informatin Bulletin Series. WHO, Undated
221. Dworkin SL, Ehrhardt AA. Going beyond " ABC" to include " GEM": Critical reflections on progress in the HIV/AIDS epidemic. Am J Public Health 2007, 97:13-8.
222. Dunkle KL, Jewkes R. Effective HIV prevention requires gender-transformative work with men. Sex Transm Infect 2007, 83:173-4.
223. Ackermann L, de K. Social factors that make South African women vulnerable to HIV infection. Health Care Women Int 2002, 23:163-72.
224. Kalichman S. Gender attitudes, sexual violence and HIV/AIDS risks among men and women in Cape Town. J Sex Res 2005, 42:299-305.
225. Adimora AA, Schoenbach VJ. Contextual factors and the black-white disparity in heterosexual HIV transmission. Epidemiology 2002, 13:707-12.
226. Morris M, Kretzschmar M. Concurrent partnerships and the spread of HIV. AIDS 1997, 11:641-8.
227. Epstein H. The invisible cure: Africa the west and the fight against AIDS 2007, New York, Farrar, Straus & Giroux
228. Johnson CA, Reddy V, Sandfort T, Rispel L. What we know about same sex practicing people and HIV in Africa. From social silence to social science; same sex sexuality, HIV and AIDS and gender in South Africa 2009, 31-42. In, eds., Capetown, HRSC Press